Drug intelligence / Profile preview

LNO-L02

Development stage: Preclinical
Lead developer: Linno Pharmaceuticals
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

LNO-L02 is a preclinical-stage therapeutic candidate being developed by Linno Pharmaceuticals for the treatment of metabolic diseases. The drug utilizes a lipid nanoparticle (LNP) delivery system, a modality typically employed to transport nucleic acid-based payloads, such as mRNA or siRNA, to specific target tissues like the liver. While the specific molecular target and the nature of the therapeutic cargo have not been publicly disclosed, the program is part of Linno Pharmaceuticals' pipeline focused on leveraging proprietary LNP technology to address unmet needs in metabolic health.

Beyond the preview

Go deeper on LNO-L02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNO-L02.

Explore the full profile